TECH
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Bio-Techne Corp develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments: Protein Sciences, which offers biological reagents like cytokines, growth factors, and antibodies, along with automated protein analysis instruments; and Diagnostics and Spatial Biology, which provides diagnostic assays, controls, and spatial genomic analysis tools. Key brands include R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, and RNAscope. Bio-Techne serves customers in academia, pharmaceutical and biotech industries, and clinical laboratories across North America, Europe, and Asia. Founded in 1976 as Research and Diagnostic Systems, Inc., the company expanded its portfolio through acquisitions such as Lunaphore and Wilson Wolf, and maintains a distribution partnership with Thermo Fisher Scientific.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Biotechnology Homepage bio-techne.com
Sector Healthcare IR page investors.bio-techne.com
Tags
protein analysis, spatial biology, cell and gene therapy, molecular diagnostics, biological reagents, immunoassays, western blotting, tissue biopsy analysis, oncology testing, contract manufacturing, R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, RNAscope, Lunaphore, Wilson Wolf, Amplidex, Quantidex, Simple Western, Simple Plex, iCE Maurice, Proteome Profiler
Press page investors.bio-techne.com/press-releases

Metrics

Valuation  
Market cap $ 11.382B
Market cap (USD) $ 11.382B
P/E 65.88
PEG —
P/BV 5.26
P/S 9.27
P/OCF 33.71
P/FCF 36.93
Dividend yield 0.44%
Turnover / mcap —
Returns  
ROE 9.0%
ROI 9.5%
ROIC 9.9%
Profit margin 15.0%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -13.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.215B 1.22B 1.159B 1.137B 1.106B 931.032M 738.691M 714.006M 642.993M 563.003M 499.023M 452.246M 357.763M 310.575M 314.56M 289.962M 269.047M 178.652M 161.257M 145.011M — 115.357M 103.838M
Net profit 181.862M 73.4M 168.105M 285.263M 272.051M 140.41M 229.296M 96.072M 126.15M 76.086M 104.476M 107.735M 110.948M 112.561M 112.331M 112.302M 109.776M 66.132M 52.928M 45.396M 27.13M 34.045M 26.583M
Free cash flow 263.223M 256.55M 236.104M 216.149M 280.364M 307.863M 153.473M 156.208M 149.433M 128.269M 126.972M 119.454M 122.941M 101.108M 120.729M 123.564M 106.616M — 61.843M 38.895M 5.391M 39.557M 8.372M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 70.65 51.45 71.65 81.63 346.64 450.26 264.07 208.49 147.95 117.5 112.77 98.47 91 65 62.61 81.2 63.33 — — — — — —
Price performance 12m 0.37 -0.28 -0.12 -0.76 -0.23 0.71 0.27 0.41 0.26 0.04 0.15 0.08 0.4 0.04 -0.23 0.28 0 — — — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 117M 120M 137M 123M 145M 195M 218M 241M 207M 217M
↳ YoY growth +25.1% +3.0% +14.3% -10.9% +18.6% +33.8% +12.3% +10.5% -14.3% +4.7%
↳ 5y CAGR +26.8% +25.8% +23.5% +11.8% +9.3% +10.7% +12.7% +11.9% +11.0% +8.3%
Borrowings, current (USD) — — 12.5M 12.5M 12.5M 12.5M — — — —
Borrowings, non-current (USD) 344M 339M 493M 344M 329M 243M 350M 319M 346M 200M
Lease liabilities (USD) — — 0.00 76.8M 79.2M 70.1M 105M 101M 98.1M 89.1M
Cash and deposits (USD) 91.6M 122M 101M 147M 199M 173M 181M 152M 162M 265M
Intangible assets (USD) 452M 446M 579M 517M 616M 532M 535M 507M 366M 303M
Right-of-use assets (USD) — — 0.00 71.5M 73.8M 65.6M 98.3M 91.3M 73.4M 67.3M
Net debt (borrowings + leases - cash) (USD) 252M 217M 404M 287M 221M 153M 274M 268M 282M 24.4M
Cash flow detail
Operating cash flow (USD) 143M 170M 182M 205M 352M 325M 254M 299M 288M 292M
Purchases of property, plant and equipment (USD) -15.2M -20.9M -25.4M -51.7M -44.3M -44.9M -38.2M -62.9M -31M -28.9M
Change in inventories (cash effect) (USD) -732,000 -13.3M -13.6M -14.9M -7.14M -32M -30.2M -14.2M -18.1M -8.23M
Change in payables (cash effect) (USD) 5.7M 5.03M 6.1M 10.3M 19.1M 12.7M -7.91M 25.8M -14M 3.18M
Dividends paid (cash effect) (USD) -47.3M -48M -48.4M -48.9M -49.6M -50.2M -50.3M -50.4M -50.4M -49.9M
Share buybacks (cash effect) (USD) — 0.00 -15.4M -50.1M -43.2M -161M -19.6M -80M -276M -41.7M
Interest paid (cash effect) (USD) -7.45M -9.84M -21.5M -18.6M -13.6M -11M -8.37M -14.5M -19M -14.4M
Income taxes paid (cash effect) (USD) -42.9M -35.1M -36.8M -42M -21M -30.3M -88.4M -65.3M -74.4M -64.1M
Share-based compensation (USD) 14.6M 28.2M 32.3M 32.4M 49M 42.2M 39.2M 38M 40.8M 41.4M
Free cash flow (OCF - PPE - intangibles) (USD) 128M 149M 156M 153M 308M 280M 216M 236M 257M 263M
Income detail
Research and development expense (USD) 53.5M 55.3M 62.4M 65.2M 70.6M 87.1M 92.5M 96.7M 99.5M 94.8M
↳ 5y CAGR +13.9% +13.6% +15.1% +9.8% +9.3% +10.2% +10.8% +9.1% +8.8% +6.1%
Total comprehensive income (USD) 97.6M 130M 82M 216M 180M 254M 294M 156M 91.8M 171M
Comprehensive income to owners (USD) 97.6M 130M 82M 216M 180M 254M 294M 156M 91.8M 171M
Reported Sep 7, 2017 Aug 26, 2020 Nov 6, 2019 Aug 26, 2020 Aug 25, 2021 Aug 24, 2022 Aug 23, 2023 Aug 22, 2024 Aug 22, 2025 Aug 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BIO-TECHNE DECLARES DIVIDEND Bull 0 Bear 0 Capital return

Download as PDF

November 03, 2026

MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis, as applicable.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2026 and has approximately 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­techne.com .

**Forward-Looking Statements
**Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including statements regarding the payment and timing of the quarterly dividend and the pending acquisition of Bio-Techne by Merck KGaA, Darmstadt, Germany. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including: the timing of completion of the pending transaction, including whether it is completed on or before the dividend record date; the satisfaction of the conditions to the pending transaction, including receipt of required shareholder and regulatory approvals; the effect of the announcement or pendency of the transaction on Bio-Techne's business, operations and stock price; and the other factors described under "Risk Factors" in Bio-Techne's Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and its subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact: David Clair, Vice President, Investor Relations
[email protected]
612-656-4416

Bio-Techne

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302928623.html

SOURCE Bio-Techne Corporation

Released November 3, 2026

Bio-Techne

614 McKinley Place NE
Minneapolis, MN 55413
USA

TEL 612 379 2956
Toll-free 800 343 7475
FAX 612 656 4400

Who We Are

Investor Relations

Stay Connected

Utility Footer Menu

© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.

This site uses cookies and similar technologies ("cookies") as strictly necessary for site operation. We and our partners also would like to set additional cookies to enable site performance analytics, functionality, advertising and social media features. See our Privacy Policy and Cookie Policy for details. You can change your cookie preferences in our Cookie Settings.

Cookies Settings

Company Logo

Cookie Settings

You can click the different headings below to find out more information about each category of cookies and similar technologies ("cookies") and change the default settings. See our Cookie Policy for details.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems.

Advertising and Social Media Cookies

Advertising and Social Media Cookies

Advertising cookies are set by us and our advertising partners to collect information about your use of the site, our communications, and other online services over time and with different browsers and devices. This information is used to show you ads online that may interest you and measure the ads’ performance. Social media cookies are set by social media platforms to enable you to share content on those platforms, and are capable of tracking information about your activity across other online services for use as described in their privacy policies.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Save Settings

Powered by Onetrust

Download as PDF

October 08, 2026

  • Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications
  • New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America
  • Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing

MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.

The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for advanced cell therapy manufacturing, the facility enhances Bio-Techne's ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply.

"As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide."

The Bristol expansion is the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its extensive GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a leading manufacturer of cell culture devices including the widely adopted G-Rex® platform, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. Collectively, these capabilities help customers transition seamlessly from research through clinical development and commercial production.

Cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently while meeting evolving regulatory expectations. Bio-Techne addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines. Recent industry discussions have increasingly highlighted manufacturing scalability as a critical factor in enabling broader patient access to advanced therapies, reinforcing the importance of investments such as the Bristol expansion.

"The opening of our Bristol facility represents more than additional manufacturing capacity," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It strengthens Bio-Techne's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply."

The Bristol facility is fully operational and is manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide.

ABOUT BIO-TECHNE

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

October 08, 2026

  • Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications

  • New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America

  • Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing

MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.

The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for advanced cell therapy manufacturing, the facility enhances Bio-Techne's ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply.

"As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide."

The Bristol expansion is the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its extensive GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a leading manufacturer of cell culture devices including the widely adopted G-Rex® platform, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. Collectively, these capabilities help customers transition seamlessly from research through clinical development and commercial production.

Cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently while meeting evolving regulatory expectations. Bio-Techne addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines. Recent industry discussions have increasingly highlighted manufacturing scalability as a critical factor in enabling broader patient access to advanced therapies, reinforcing the importance of investments such as the Bristol expansion.

"The opening of our Bristol facility represents more than additional manufacturing capacity," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It strengthens Bio-Techne's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply."

The Bristol facility is fully operational and is manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide.

Prompts

Bio-Techne Corp (ticker TECH), listed in United States.

Company History

Date Change Detail
Nov 3, 2014 Renamed TECHNE CORP /MN/ → BIO-TECHNE CORP

ETFs Holding Bio-Techne Corp

ETF Weight in ETF Shares Market value As of
CVAR 1.46% 8,709 $ 627.832K Jul 31, 2026
EVNT 1.02% 1,838 $ 132.906K Aug 31, 2026
SEIS 0.22% 18,098 $ 1.279M Jun 30, 2026
AVMC 0.10% 7,961 $ 579.481K Nov 16, 2026
MSSM 0.08% 7,982 $ 577.178K Aug 31, 2026
CAPE 0.05% 1,711 $ 120.882K Jun 30, 2026
DFSU 0.02% 6,829 $ 497.424K Nov 12, 2026
AVLC 0.02% 4,026 $ 293.053K Nov 16, 2026
AAUS 0.02% 1,469 $ 110K Nov 18, 2026
DFAC 0.01% 176,888 $ 12.885M Nov 12, 2026
HCMT 0.01% 1,089 $ 78.506K Jul 31, 2026
MSLC 0.01% 5,937 $ 429.304K Aug 31, 2026
AVUS 0.01% 14,737 $ 1.073M Nov 16, 2026
CSHP 0.01% 267 $ 19.435K Nov 16, 2026
AVSU 0.01% 841 $ 61.216K Nov 16, 2026
GSPY 0.01% 499 $ 36.322K Nov 17, 2026
DCOR 0.01% 34,652 $ 2.524M Nov 12, 2026
DFUV 0.00% 1,777 $ 129.437K Nov 12, 2026
CORO 0.00% 99 $ 7,187.16 Nov 16, 2026